Wayne W Hancock

List of Publications by Year
in descending order

277	23,819	6124	10399
papers	citations	83 h-index	144 g-index

278	278	278	23235
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clinically available immunosuppression averts rejection but not systemic inflammation after porcine islet xenotransplant in cynomolgus macaques. American Journal of Transplantation, 2022, 22, 745-760.	2.6	9
2	HDAC2 targeting stabilizes the CoREST complex in renal tubular cells and protects against renal ischemia/reperfusion injury. Scientific Reports, 2021, 11, 9018.	1.6	10
3	A Biological Circuit Involving Mef2c, Mef2d, and Hdac9 Controls the Immunosuppressive Functions of CD4+Foxp3+ T-Regulatory Cells. Frontiers in Immunology, 2021, 12, 703632.	2.2	7
4	Obesity-related IL-18 Impairs T-Regulatory Cell Function and Promotes Lung Ischemiaâ€"Reperfusion Injury. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1060-1074.	2.5	22
5	Kynurenine induces T cell fat catabolism and has limited suppressive effects in vivo. EBioMedicine, 2021, 74, 103734.	2.7	20
6	Tubastatin-A Mediated Protection from Acetaminophen-Induced Liver Injury is Preserved in Lymphocyte and Macrophage Deficient Mice. Journal of the American College of Surgeons, 2020, 231, e224.	0.2	0
7	The CCR2/MCP-1 Chemokine Pathway and Lung Adenocarcinoma. Cancers, 2020, 12, 3723.	1.7	17
8	Lactate Limits T Cell Proliferation via the NAD(H) Redox State. Cell Reports, 2020, 33, 108500.	2.9	135
9	Tissue metabolic profiling shows that saccharopine accumulates during renal ischemic-reperfusion injury, while kynurenine and itaconate accumulate in renal allograft rejection. Metabolomics, 2020, 16, 65.	1.4	8
10	Limited efficacy of rapamycin monotherapy in vascularized composite allotransplantation. Transplant Immunology, 2020, 61, 101308.	0.6	0
11	Donor bone-marrow CXCR4+ Foxp3+ T-regulatory cells are essential for costimulation blockade-induced long-term survival of murine limb transplants. Scientific Reports, 2020, 10, 9292.	1.6	5
12	Donor-host Lymphatic Anastomosis After Murine Lung Transplantation. Transplantation, 2020, 104, 511-515.	0.5	12
13	HDAC10 deletion promotes Foxp3+ T-regulatory cell function. Scientific Reports, 2020, 10, 424.	1.6	42
14	Inhibiting the coregulator CoREST impairs Foxp3+ Treg function and promotes antitumor immunity. Journal of Clinical Investigation, 2020, 130, 1830-1842.	3.9	41
15	MEF2D sustains activation of effector Foxp3+ Tregs during transplant survival and anticancer immunity. Journal of Clinical Investigation, 2020, 130, 6242-6260.	3.9	15
16	Loss of HDAC6 alters gut microbiota and worsens obesity. FASEB Journal, 2019, 33, 1098-1109.	0.2	36
17	3236 Identification of exhaustive markers in cytotoxic T-cells to guide immune modulation in hepatocellular carcinoma ex vivo. Journal of Clinical and Translational Science, 2019, 3, 13-13.	0.3	0
18	Adipose tissue quantification and primary graft dysfunction after lung transplantation: The Lung Transplant Body Composition study. Journal of Heart and Lung Transplantation, 2019, 38, 1246-1256.	0.3	29

#	Article	IF	Citations
19	Complementary Roles of GCN5 and PCAF in Foxp3+ T-Regulatory Cells. Cancers, 2019, 11, 554.	1.7	9
20	Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer. Science Translational Medicine, 2019, 11, .	5.8	169
21	Sirtuin-1 in immunotherapy: A Janus-headed target. Journal of Leukocyte Biology, 2019, 106, 337-343.	1.5	32
22	Lymphatic impairment leads to pulmonary tertiary lymphoid organ formation and alveolar damage. Journal of Clinical Investigation, 2019, 129, 2514-2526.	3.9	81
23	Human neutrophils can mimic myeloid-derived suppressor cells (PMN-MDSC) and suppress microbead or lectin-induced T cell proliferation through artefactual mechanisms. Scientific Reports, 2018, 8, 3135.	1.6	35
24	Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. Nature Communications, 2018, 9, 53.	5.8	175
25	Histone/protein deacetylase inhibitor therapy for enhancement of Foxp3+ T-regulatory cell function posttransplantation. American Journal of Transplantation, 2018, 18, 1596-1603.	2.6	53
26	Utility of IL-2 Complexes in Promoting the Survival of Murine Orthotopic Forelimb Vascularized Composite Allografts. Transplantation, 2018, 102, 70-78.	0.5	10
27	Use of TGF-beta plus Rapamycin to Induce Foxp3, promote iTreg Development and Suppressive Function, and Induce Long-Term Allograft Survival. Transplantation, 2018, 102, S329.	0.5	0
28	Histone Deacetylase- 11 Gene Deletion is Protective in Renal Ischemia-Reperfusion Injury. Transplantation, 2018, 102, S704.	0.5	0
29	Histone Deacetylase Inhibition Provides Tissue-Specific Protection after Renal and Liver Ischemia Reperfusion Injury. Journal of the American College of Surgeons, 2018, 227, S253.	0.2	0
30	Histone Deacetylase-6 Inhibition is Protective in Liver Ischemia-Reperfusion Injury and Acetaminophen Toxicity in a Murine Model. Transplantation, 2018, 102, S353.	0.5	1
31	How little is known about the role of human FOXP3+ Tregs in tumors. Expert Opinion on Therapeutic Targets, 2018, 22, 655-658.	1.5	4
32	MEF2 and the tumorigenic process, hic sunt leones. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1870, 261-273.	3.3	47
33	Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments. Cell Metabolism, 2017, 25, 1282-1293.e7.	7.2	741
34	Suppression by human FOXP3 ⁺ regulatory T cells requires FOXP3-TIP60 interactions. Science Immunology, 2017, 2, .	5.6	47
35	Regulatory T cell signatures in liver transplant recipients successfully weaned from immunosuppression: Getting from here to there. Liver Transplantation, 2017, 23, 875-877.	1.3	1
36	T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model. Blood, 2017, 130, 146-155.	0.6	54

#	Article	IF	Citations
37	The Effects of Tacrolimus on T-Cell Proliferation Are Short-Lived: A Pilot Analysis of Immune Function Testing. Transplantation Direct, 2017, 3, e199.	0.8	13
38	Proximity Ligation Assay to Quantify Foxp3 Acetylation in Regulatory T Cells. Methods in Molecular Biology, 2017, 1510, 287-293.	0.4	7
39	Active site-targeted covalent irreversible inhibitors of USP7 impair the functions of Foxp3+ T-regulatory cells by promoting ubiquitination of Tip60. PLoS ONE, 2017, 12, e0189744.	1.1	41
40	Histone/protein deacetylase 11 targeting promotes Foxp3+ Treg function. Scientific Reports, 2017, 7, 8626.	1.6	64
41	Models of Lung Transplant Research: a consensus statement from the National Heart, Lung, and Blood Institute workshop. JCI Insight, 2017, 2, .	2.3	55
42	Human lung tumor FOXP+ Tregs upregulate four â€œTreg-lockingâ€•transcription factors. JCI Insight, 2017, 2, .	2.3	56
43	Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer. Cancer Cell, 2016, 30, 120-135.	7.7	311
44	Targeting Sirtuin-1 prolongs murine renal allograft survival and function. Kidney International, 2016, 89, 1016-1026.	2.6	31
45	HDAC5 controls the functions of Foxp3⁺ Tâ€•regulatory and CD8⁺ T cells. International Journal of Cancer, 2016, 138, 2477-2486.	2.3	67
46	Isoform-Selective HDAC Inhibitor Therapy for Transplantation. Transplantation, 2016, 100, 1597-1598.	0.5	7
47	Ubiquitin-specific Protease-7 Inhibition Impairs Tip60-dependent Foxp3 + T-regulatory Cell Function and Promotes Antitumor Immunity. EBioMedicine, 2016, 13, 99-112.	2.7	86
48	Standardization, Evaluation, and Area-Under-Curve Analysis of Human and Murine Treg Suppressive Function. Methods in Molecular Biology, 2016, 1371, 43-78.	0.4	35
49	Improved renal ischemia tolerance in females influences kidney transplantation outcomes. Journal of Clinical Investigation, 2016, 126, 1968-1977.	3.9	112
50	Mesenchymal Stromal Cell-Derived Factors Promote Tissue Repair in a Small-for-Size Ischemic Liver Model but Do Not Protect against Early Effects of Ischemia and Reperfusion Injury. Journal of Immunology Research, 2015, 2015, 1-13.	0.9	7
51	Pim-2 Kinase Influences Regulatory T Cell Function and Stability by Mediating Foxp3 Protein N-terminal Phosphorylation. Journal of Biological Chemistry, 2015, 290, 20211-20220.	1.6	74
52	The inflammatory phenotype of the fibrous plate is distinct from the liver and correlates with clinical outcome in biliary atresia. Pathology Research and Practice, 2015, 211, 252-260.	1.0	4
53	Essential role of mitochondrial energy metabolism in Foxp3 ⁺ Tâ€•regulatory cell function and allograft survival. FASEB Journal, 2015, 29, 2315-2326.	0.2	213
54	Thiol-Based Potent and Selective HDAC6 Inhibitors Promote Tubulin Acetylation and T-Regulatory Cell Suppressive Function. ACS Medicinal Chemistry Letters, 2015, 6, 1156-1161.	1.3	36

#	Article	IF	Citations
55	An optimized disaggregation method for human lung tumors that preserves the phenotype and function of the immune cells. Journal of Leukocyte Biology, 2015, 97, 201-209.	1.5	54
56	FOXP3+ regulatory T cell development and function require histone/protein deacetylase 3. Journal of Clinical Investigation, 2015, 125, 1111-1123.	3.9	76
57	Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. Journal of Clinical Investigation, 2014, 124, 5466-5480.	3.9	483
58	A Novel Role for Histone Deacetylase 6 in the Regulation of the Tolerogenic STAT3/IL-10 Pathway in APCs. Journal of Immunology, 2014, 193, 2850-2862.	0.4	106
59	Two Histone/Protein Acetyltransferases, CBP and p300, Are Indispensable for Foxp3⁺ T-Regulatory Cell Development and Function. Molecular and Cellular Biology, 2014, 34, 3993-4007.	1.1	75
60	Effects of histone deacetylase inhibitors on alloresponses. Lancet Oncology, The, 2014, 15, 10-11.	5.1	4
61	Dynamic Interactions between TIP60 and p300 Regulate FOXP3 Function through a Structural Switch Defined by a Single Lysine on TIP60. Cell Reports, 2014, 7, 1471-1480.	2.9	89
62	Genetic Variation in the Prostaglandin E₂ Pathway Is Associated with Primary Graft Dysfunction. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 567-575.	2.5	32
63	Regulation of T Cell Differentiation and Alloimmunity by the Cyclin-Dependent Kinase Inhibitor p18ink4c. PLoS ONE, 2014, 9, e91587.	1.1	8
64	Inhibition of p300 impairs Foxp3+ T regulatory cell function and promotes antitumor immunity. Nature Medicine, 2013, 19, 1173-1177.	15.2	168
65	Mbd2 Promotes Foxp3 Demethylation and T-Regulatory-Cell Function. Molecular and Cellular Biology, 2013, 33, 4106-4115.	1.1	86
66	Foxp3+ T-regulatory cells require DNA methyltransferase 1 expression to prevent development of lethal autoimmunity. Blood, 2013, 121, 3631-3639.	0.6	72
67	Function of GATA Factors in the Adult Mouse Liver. PLoS ONE, 2013, 8, e83723.	1.1	35
68	Indoleamine 2,3-Dioxygenase and Metabolites Protect Murine Lung Allografts and Impair the Calcium Mobilization of T Cells. American Journal of Respiratory Cell and Molecular Biology, 2012, 47, 405-416.	1.4	24
69	Combination of isoform-selective histone/protein deacetylase inhibitors improves Foxp3+ T-regulatory cell function. Cell Cycle, 2012, 11, 3351-3352.	1.3	8
70	Cyclin-Dependent Kinase 2 Controls Peripheral Immune Tolerance. Journal of Immunology, 2012, 189, 5659-5666.	0.4	57
71	Histone Deacetylases 6 and 9 and Sirtuin-1 Control Foxp3 ⁺ Regulatory T Cell Function Through Shared and Isoform-Specific Mechanisms. Science Signaling, 2012, 5, ra45.	1.6	181
72	Histone/protein deacetylases and T-cell immune responses. Blood, 2012, 119, 2443-2451.	0.6	123

#	Article	IF	Citations
73	Second-Generation Histone Deacetylase 6 Inhibitors Enhance the Immunosuppressive Effects of Foxp3+ T-Regulatory Cells. Journal of Medicinal Chemistry, 2012, 55, 639-651.	2.9	88
74	Substrate Rigidity Regulates Human T Cell Activation and Proliferation. Journal of Immunology, 2012, 189, 1330-1339.	0.4	230
75	Structural and Biological Features of FOXP3 Dimerization Relevant to Regulatory T Cell Function. Cell Reports, 2012, 1, 665-675.	2.9	83
76	Two Lysines in the Forkhead Domain of Foxp3 Are Key to T Regulatory Cell Function. PLoS ONE, 2012, 7, e29035.	1.1	29
77	Physical Interaction of Histone Deacetylase 6 (HDAC6) with STAT3 Regulates IL-10 Gene Expression and Immune Tolerance Mediated by Antigen-Presenting Cells (APCs). Blood, 2012, 120, 829-829.	0.6	0
78	Histone/protein deacetylases control Foxp3 expression and the heat shock response of T-regulatory cells. Current Opinion in Immunology, 2011, 23, 670-678.	2.4	100
79	Immunogenetics and transplantation. Current Opinion in Immunology, 2011, 23, 639-640.	2.4	0
80	Sirtuin-1 Targeting Promotes Foxp3⁺ T-Regulatory Cell Function and Prolongs Allograft Survival. Molecular and Cellular Biology, 2011, 31, 1022-1029.	1.1	184
81	Histone Deacetylase 6 and Heat Shock Protein 90 Control the Functions of Foxp3⁺ T-Regulatory Cells. Molecular and Cellular Biology, 2011, 31, 2066-2078.	1.1	216
82	Herpesvirus entry mediator regulates hypoxia-inducible factorâ€“1Î± and erythropoiesis in mice. Journal of Clinical Investigation, 2011, 121, 4810-4819.	3.9	12
83	Epigenetic Modulation of STAT3 by Histone Deacetylase 6 (HDAC6) Regulates IL-10 Gene Expression and Immune Tolerance Mediated by Antigen-Presenting Cells (APCs). Blood, 2011, 118, 519-519.	0.6	2
84	Helios Expression Is a Marker of T Cell Activation and Proliferation. PLoS ONE, 2011, 6, e24226.	1.1	312
85	Histone Deacetylase 11 (HDAC11) Is a Regulatory Checkpoint of T-Cell Function: Implications for T-Cell Adoptive Immunotherapy. Blood, 2011, 118, 359-359.	0.6	0
86	Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. Clinical Immunology, 2010, 136, 348-363.	1.4	124
87	Histone acetyltransferase mediated regulation of FOXP3 acetylation and Treg function. Current Opinion in Immunology, 2010, 22, 583-591.	2.4	76
88	Inhibition of HDAC9 Increases T Regulatory Cell Function and Prevents Colitis in Mice. Gastroenterology, 2010, 138, 583-594.	0.6	209
89	Epigenetic Regulation of Regulatory T-Cells: Impact on Autoimmunity and Graft Rejection. Blood, 2010, 116, SCI-23-SCI-23.	0.6	0
90	Regulatory Allospecific T Cell Clones Abrogate Chronic Allograft Rejection. Journal of the American Society of Nephrology: JASN, 2009, 20, 820-830.	3.0	13

#	Article	IF	Citations
91	Reduced Cytotoxic Function of Effector CD8+ T Cells Is Responsible for Indoleamine 2,3-Dioxygenase-Dependent Immune Suppression. Journal of Immunology, 2009, 183, 1022-1031.	0.4	78
92	Foxp3 Processing by Proprotein Convertases and Control of Regulatory T Cell Function. Journal of Biological Chemistry, 2009, 284, 5709-5716.	1.6	36
93	BTLA targeting modulates lymphocyte phenotype, function, and numbers and attenuates disease in nonobese diabetic mice. Journal of Leukocyte Biology, 2009, 86, 41-51.	1.5	28
94	Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Experimental and Molecular Pathology, 2009, 87, 99-104.	0.9	115
95	Using histone deacetylase inhibitors to enhance Foxp3⁺ regulatory Tâ€cell function and induce allograft tolerance. Immunology and Cell Biology, 2009, 87, 195-202.	1.0	81
96	Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nature Reviews Drug Discovery, 2009, 8, 969-981.	21.5	163
97	Pirfenidone Inhibits T-Cell Activation, Proliferation, Cytokine and Chemokine Production, and Host Alloresponses. Transplantation, 2009, 88, 330-338.	0.5	49
98	Three Distinct Domains Contribute to Nuclear Transport of Murine Foxp3. PLoS ONE, 2009, 4, e7890.	1.1	38
99	Regulatory T Cell Expression of Herpesvirus Entry Mediator Suppresses the Function of B and T Lymphocyte Attenuator-Positive Effector T Cells. Journal of Immunology, 2008, 180, 6649-6655.	0.4	83
100	TGF-Î² and IL-6 signals modulate chromatin binding and promoter occupancy by acetylated FOXP3. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14023-14027.	3.3	145
101	Primary Coenzyme Q Deficiency in Pdss2 Mutant Mice Causes Isolated Renal Disease. PLoS Genetics, 2008, 4, e1000061.	1.5	109
102	Inhibition of the Alloimmune Response through the Generation of Regulatory T Cells by a MHC Class II-Derived Peptide. Journal of Immunology, 2008, 181, 7499-7506.	0.4	11
103	Mechanisms Underlying Blockade of Allograft Acceptance by TLR Ligands. Journal of Immunology, 2008, 181, 1692-1699.	0.4	82
104	Prolongation of Cardiac and Islet Allograft Survival by a Blocking Hamster Anti-Mouse CXCR3 Monoclonal Antibody. Transplantation, 2008, 86, 137-147.	0.5	70
105	Resistance of Foxp3+ Regulatory T Cells to Nur77-Induced Apoptosis Promotes Allograft Survival. PLoS ONE, 2008, 3, e2321.	1.1	28
106	Negative and Positive Co-Signaling With Anti-BTLA (PJ196) and CTLA4Ig Prolongs Islet Allograft Survival. Transplantation, 2007, 84, 1368-1372.	0.5	26
107	Delayed and Deficient Dermal Maturation in Mice Lacking the CXCR3 ELR-Negative CXC Chemokine Receptor. American Journal of Pathology, 2007, 171, 484-495.	1.9	97
108	Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease. Blood, 2007, 109, 4097-4104.	0.6	66

#	Article	IF	Citations
109	FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 4571-4576.	3.3	370
110	Programmed cell deathâ€„1 (PDâ€1) and its ligand PDâ€L1 are required for allograft tolerance. European Journal of Immunology, 2007, 37, 2983-2990.	1.6	68
111	Biochemistry and therapeutic implications of mechanisms involved in FOXP3 activity in immune suppression. Current Opinion in Immunology, 2007, 19, 583-588.	2.4	36
112	Histone deacetylase inhibitors and transplantation. Current Opinion in Immunology, 2007, 19, 589-595.	2.4	36
113	Deacetylase inhibition promotes the generation and function of regulatory T cells. Nature Medicine, 2007, 13, 1299-1307.	15.2	835
114	Regulating regulatory T cells to achieve transplant tolerance. Hepatobiliary and Pancreatic Diseases International, 2007, 6, 348-57.	0.6	16
115	The mitochondrial and kidney disease phenotypes of kd/kd mice under germfree conditions. Journal of Autoimmunity, 2006, 26, 1-6.	3.0	41
116	Differential Expression of Profibrotic and Growth Factors in Chronic Allograft Nephropathy. Transplantation, 2006, 81, 342-349.	0.5	52
117	Coinhibitory T-Cell Signaling in Islet Allograft Rejection and Tolerance. Cell Transplantation, 2006, 15, 105-119.	1.2	65
118	HISTONE DEACETYLASE INHIBITORS (HDACI) ENHANCE FOXP3+ REGULATORY T CELL (TREG) FUNCTIONS AND SUPPRESS INFLAMMATORY BOWEL DISEASE (IBD). Journal of Pediatric Gastroenterology and Nutrition, 2006, 43, E33.	0.9	0
119	Chemokines and Their Receptors in Islet Allograft Rejection and as Targets for Tolerance Induction. Cell Transplantation, 2006, 15, 295-309.	1.2	30
120	Selective Neutralization of the Chemokine TCA3 Reduces the Increased Injury of Partial Versus Whole Liver Transplants Induced by Cold Preservation. Transplantation, 2006, 82, 1501-1509.	0.5	8
121	Safety and Efficacy of a Calcineurin Inhibitor Avoidance Regimen in Pediatric Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2006, 17, 1735-1745.	3.0	62
122	Allograft Rejection Requires STAT5a/b-Regulated Antiapoptotic Activity in T Cells but Not B Cells. Journal of Immunology, 2006, 176, 128-137.	0.4	11
123	CXCR3+CD4+ T Cells Mediate Innate Immune Function in the Pathophysiology of Liver Ischemia/Reperfusion Injury. Journal of Immunology, 2006, 176, 6313-6322.	0.4	51
124	The Cyclin-Dependent Kinase Inhibitor p27kip1 Is Required for Transplantation Tolerance Induced by Costimulatory Blockade. Journal of Immunology, 2006, 177, 5169-5176.	0.4	31
125	Accelerated Memory Cell Homeostasis during T Cell Depletion and Approaches to Overcome It. Journal of Immunology, 2006, 176, 4632-4639.	0.4	139
126	Transcriptional Regulation by Foxp3 Is Associated with Direct Promoter Occupancy and Modulation of Histone Acetylation. Journal of Biological Chemistry, 2006, 281, 36828-36834.	1.6	197

#	Article	IF	Citations
127	PTEN inhibits IL-2 receptor-mediated expansion of CD4+CD25+ Tregs. Journal of Clinical Investigation, 2006, 116, 2521-31.	3.9	130
128	Costimulation blockade of both inducible costimulator and CD40 ligand induces dominant tolerance to islet allografts and prevents spontaneous autoimmune diabetes in the NOD mouse. Diabetes, 2006, 55, 27-33.	0.3	42
129	Chemokines and their receptors in islet allograft rejection and as targets for tolerance induction. Cell Transplantation, 2006, 15, 295-309.	1.2	15
130	Systemic Transforming Growth Factor-??1 Gene Therapy Induces Foxp3+ Regulatory Cells, Restores Self-Tolerance, and Facilitates Regeneration Of Beta Cell Function in Overtly Diabetic Nonobese Diabetic Mice. Transplantation, 2005, 79, 1091-1096.	0.5	77
131	Selectin Blockade Plus Therapy with Low-Dose Sirolimus and Cyclosporin A Prevent Brain Death-Induced Renal Allograft Dysfunction. American Journal of Transplantation, 2005, 5, 662-670.	2.6	23
132	B7-H3 promotes acute and chronic allograft rejection. European Journal of Immunology, 2005, 35, 428-438.	1.6	91
133	Messenger RNA forFOXP3in the Urine of Renal-Allograft Recipients. New England Journal of Medicine, 2005, 353, 2342-2351.	13.9	501
134	Permanent Survival of Fully MHC-Mismatched Islet Allografts by Targeting a Single Chemokine Receptor Pathway. Journal of Immunology, 2005, 175, 6311-6318.	0.4	23
135	Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. Journal of Experimental Medicine, 2005, 201, 1037-1044.	4.2	348
136	Differential Effects of B and T Lymphocyte Attenuator and Programmed Death-1 on Acceptance of Partially versus Fully MHC-Mismatched Cardiac Allografts. Journal of Immunology, 2005, 175, 5774-5782.	0.4	113
137	Glomerular and Tubular Epithelial Defects in kd/kd Mice Lead to Progressive Renal Failure. American Journal of Nephrology, 2005, 25, 604-610.	1.4	14
138	Intact type 1 immunity and immune-associated coagulative responses in mice lacking IFNÂ-inducible fibrinogen-like protein 2. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3005-3010.	3.3	46
139	Selectin Inhibitor Bimosiamose Prolongs Survival of Kidney Allografts by Reduction in Intragraft Production of Cytokines and Chemokines. Journal of the American Society of Nephrology: JASN, 2004, 15, 2893-2901.	3.0	31
140	Targeting IL-15 Receptor-Bearing Cells with an Antagonist Mutant IL-15/Fc Protein Prevents Disease Development and Progression in Murine Collagen-Induced Arthritis. Journal of Immunology, 2004, 173, 5818-5826.	0.4	127
141	Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney International, 2004, 65, 2390-2397.	2.6	177
142	Mutant prenyltransferase-like mitochondrial protein (PLMP) and mitochondrial abnormalities in kd/kd mice. Kidney International, 2004, 66, 20-28.	2.6	46
143	Homeostatic proliferation is a barrier to transplantation tolerance. Nature Medicine, 2004, 10, 87-92.	15.2	388
144	Multiple Combination Therapies Involving Blockade of ICOS/B7RP-1 Costimulation Facilitate Long-Term Islet Allograft Survival. American Journal of Transplantation, 2004, 4, 526-536.	2.6	68

#	Article	IF	Citations
145	Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-Î³ production of CD8+ T cells in secondary progressive multiple sclerosis. Journal of Neuroimmunology, 2004, 146, 189-198.	1.1	45
146	Bcl-XL Expression in Stem Cells Facilitates Engraftment and Reduces the Need for Host Conditioning During Bone Marrow Transplantation. American Journal of Transplantation, 2004, 4, 58-64.	2.6	59
147	BAFF binding to T cell-expressed BAFF-R costimulates T cell proliferation and alloresponses. European Journal of Immunology, 2004, 34, 2750-2759.	1.6	119
148	Donor hypertension increases graft immunogenicity and intensifies chronic changes in long-surviving renal allografts. Transplantation, 2004, 77, 43-48.	0.5	14
149	Allograft Rejection in a New Allospecific CD4+ TCR Transgenic Mouse. American Journal of Transplantation, 2003, 3, 381-389.	2.6	52
150	Viral IL-10 Gene Transfer Inhibits the Expression of Multiple Chemokine and Chemokine Receptor Genes Induced by Inflammatory or Adaptive Immune Stimuli. American Journal of Transplantation, 2003, 3, 1538-1549.	2.6	19
151	Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression. Current Opinion in Immunology, 2003, 15, 479-486.	2.4	127
152	Chemokine receptor-dependent alloresponses. Immunological Reviews, 2003, 196, 37-50.	2.8	51
153	Transplantation immunobiology. Immunological Reviews, 2003, 196, 5-6.	2.8	0
154	TRAF6 Is a Critical Factor for Dendritic Cell Maturation and Development. Immunity, 2003, 19, 353-363.	6.6	249
155	Cutting Edge: Multiple Autoimmune Pathways in kd/kd Mice. Journal of Immunology, 2003, 171, 2778-2781.	0.4	20
156	Systemic Rather Than Local Heme Oxygenase-1 Overexpression Improves Cardiac Allograft Outcomes in a New Transgenic Mouse. Journal of Immunology, 2003, 171, 1572-1580.	0.4	78
157	Nasal Vaccination with Myelin Oligodendrocyte Glycoprotein Reduces Stroke Size by Inducing IL-10-Producing CD4+ T Cells. Journal of Immunology, 2003, 171, 6549-6555.	0.4	142
158	Blocking the Monocyte Chemoattractant Protein-1/CCR2 Chemokine Pathway Induces Permanent Survival of Islet Allografts through a Programmed Death-1 Ligand-1-Dependent Mechanism. Journal of Immunology, 2003, 171, 6929-6935.	0.4	100
159	TNF Receptor-Associated Factor 6 Deficiency during Hemopoiesis Induces Th2-Polarized Inflammatory Disease. Journal of Immunology, 2003, 171, 5751-5759.	0.4	50
160	Chemokine-directed dendritic cell trafficking in allograft rejection. Current Opinion in Organ Transplantation, 2003, 8, 35-39.	0.8	5
161	Normalization of Brain Deathâ€"Induced Injury to Rat Renal Allografts by Recombinant Soluble P-Selectin Glycoprotein Ligand. Journal of the American Society of Nephrology: JASN, 2002, 13, 1937-1945.	3.0	49
162	Programmed Death-1 Targeting Can Promote Allograft Survival. Journal of Immunology, 2002, 169, 6546-6553.	0.4	219

#	Article	IF	Citations
163	Modulation of LIGHT-HVEM Costimulation Prolongs Cardiac Allograft Survival. Journal of Experimental Medicine, 2002, 195, 795-800.	4.2	111
164	Early and late injury to renal transplants from non???heart-beating donors1. Transplantation, 2002, 73, 1468-1474.	0.5	13
165	Immunopathogenesis of accelerated allograft rejection in sensitized recipients: humoral and nonhumoral mechanisms1. Transplantation, 2002, 73, 1392-1397.	0.5	32
166	Enforced c-REL deficiency prolongs survival of islet allografts1. Transplantation, 2002, 74, 291-298.	0.5	33
167	Recipient hypertension potentiates chronic functional and structural injury of rat renal allografts. Transplantation, 2002, 74, 307-314.	0.5	13
168	Proapoptotic bax is hyperexpressed in isolated human islets compared with antiapoptotic bcl-21. Transplantation, 2002, 74, 1489-1496.	0.5	44
169	Anti-CD28 Monoclonal Antibody Therapy Prevents Chronic Rejection of Renal Allografts in Rats. Journal of the American Society of Nephrology: JASN, 2002, 13, 519-527.	3.0	47
170	Chemokines and Transplant Immunobiology. Journal of the American Society of Nephrology: JASN, 2002, 13, 821-824.	3.0	46
171	DIFFERENTIAL NF-??B AND I??B GENE EXPRESSION DURING DEVELOPMENT OF CARDIAC ALLOGRAFT REJECTION VERSUS CD154 MONOCLONAL ANTIBODY-INDUCED TOLERANCE1. Transplantation, 2001, 71, 835-840.	0.5	23
172	Importance of ICOSâ€“B7RP-1 costimulation in acute and chronic allograft rejection. Nature Immunology, 2001, 2, 591-596.	7.0	301
173	Critical Role of Kupffer Cell-Derived IL-10 for Host Defense in Septic Peritonitis. Journal of Immunology, 2001, 167, 3919-3927.	0.4	87
174	Fibrinogen Stimulates Macrophage Chemokine Secretion Through Toll-Like Receptor 4. Journal of Immunology, 2001, 167, 2887-2894.	0.4	863
175	Donor-Derived Ip-10 Initiates Development of Acute Allograft Rejection. Journal of Experimental Medicine, 2001, 193, 975-980.	4.2	369
176	Expression of the Chemokine Receptor CXCR3 and Its Ligand IP-10 During Human Cardiac Allograft Rejection. Circulation, 2001, 104, 2558-2564.	1.6	192
177	BENEFICIAL EFFECTS OF TARGETING CCR5 IN ALLOGRAFT RECIPIENTS1. Transplantation, 2001, 72, 1199-1205.	0.5	150
178	Targeted deletion of CX3CR1 reveals a role for fractalkine in cardiac allograft rejection. Journal of Clinical Investigation, 2001, 108, 679-688.	3.9	145
179	Influence of Donor Brain Death on Chronic Rejection of Renal Transplants in Rats. Journal of the American Society of Nephrology: JASN, 2001, 12, 2474-2481.	3.0	119
180	Activation of the Heart by Donor Brain Death Accelerates Acute Rejection After Transplantation. Circulation, 2000, 102, 2426-2433.	1.6	182

#	Article	IF	Citations
181	DONOR BRAIN DEATH AS A RISK FACTOR FOR CHRONIC REJECTION OF RAT CARDIAC ALLOGRAFTS.. Transplantation, 2000, 69, S349.	0.5	0
182	QUANTITATIVE ANALYSIS OF NFÎºB AND IÎºB PROTEINS WITHIN MOUSE CARDIAC ALLOGRAFTS.. Transplantation, 2000, 69, S347.	0.5	0
183	Accelerated Rejection of Renal Allografts From Brain-Dead Donors. Annals of Surgery, 2000, 232, 263-271.	2.1	170
184	INTERLEUKIN-2 AND INTERFERON-?? DOUBLE KNOCKOUT MICE REJECT HETEROTOPIC CARDIAC ALLOGRAFTS. Transplantation, 2000, 70, 1378-1381.	0.5	24
185	Chemokines and their receptors in allograft rejection. Current Opinion in Immunology, 2000, 12, 511-516.	2.4	165
186	Modulation of experimental autoimmune encephalomyelitis: effect of altered peptide ligand on chemokine and chemokine receptor expression. Journal of Neuroimmunology, 2000, 110, 195-208.	1.1	93
187	Macrophage Inflammatory Protein-2 and KC Induce Chemokine Production by Mouse Astrocytes. Journal of Immunology, 2000, 165, 4015-4023.	0.4	62
188	Requirement of the Chemokine Receptor CXCR3 for Acute Allograft Rejection. Journal of Experimental Medicine, 2000, 192, 1515-1520.	4.2	591
189	The NOD Idd9 Genetic Interval Influences the Pathogenicity of Insulitis and Contains Molecular Variants of Cd30, Tnfr2, and Cd137. Immunity, 2000, 13, 107-115.	6.6	153
190	ACTIVATION OF INFLAMMATORY MEDIATORS IN RAT RENAL ISOGRAFTS BY DONOR BRAIN DEATH1. Transplantation, 2000, 69, 405-410.	0.5	165
191	DIFFERENTIAL EFFECTS OF CYCLOSPORINE A, METHYLPREDNISOLONE, MYCOPHENOLATE, AND RAPAMYCIN ON CD154 INDUCTION AND REQUIREMENT FOR NF??B. Transplantation, 2000, 70, 415-419.	0.5	149
192	Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. Journal of Clinical Investigation, 2000, 105, 35-44.	3.9	228
193	Genetic susceptibility or resistance to autoimmune encephalomyelitis in MHC congenic mice is associated with differential production of pro- and anti-inflammatory cytokines. International Immunology, 1999, 11, 1573-1580.	1.8	63
194	Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nature Medicine, 1999, 5, 1303-1307.	15.2	574
195	Islet Mass Plays a Critical Role in Initiation, but not Progression, of the Diabetogenic Process in NOD Mice. Journal of Autoimmunity, 1999, 12, 243-249.	3.0	3
196	IMMUNOMODULATORY FUNCTIONS OF HYALURONATE IN THE LEW-TO-F344 MODEL OF CHRONIC CARDIAC ALLOGRAFT REJECTION. Transplantation, 1999, 67, 909-914.	0.5	22
197	CELLULAR AND HUMORAL MECHANISMS OF VASCULARIZED ALLOGRAFT REJECTION INDUCED BY INDIRECT RECOGNITION OF DONOR MHC ALLOPEPTIDES1. Transplantation, 1999, 67, 1523-1532.	0.5	65
198	RESISTANCE OF ESTABLISHED PORCINE ISLET XENOGRAFTS TO HUMORAL REJECTION BY HYPERIMMUNE SERA. Transplantation, 1999, 68, 888-893.	0.5	12

#	Article	IF	Citations
199	Current trends in transplant immunology. Current Opinion in Nephrology and Hypertension, 1999, 8, 317-324.	1.0	8
200	Molecular basis of chronic rejection. Current Opinion in Organ Transplantation, 1999, 4, 3.	0.8	6
201	Lack of chemokine receptor CCR1 enhances Th1 responses and glomerular injury during nephrotoxic nephritis. Journal of Clinical Investigation, 1999, 104, 1549-1557.	3.9	145
202	Adenovirus-mediated gene transfer into cold-preserved liver allografts: Survival pattern and unresponsiveness following transduction with CTLA4Ig. Nature Medicine, 1998, 4, 194-200.	15.2	142
203	Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Nature Medicine, 1998, 4, 1392-1396.	15.2	451
204	Prolonged discordant xenograft survival and delayed xenograft rejection in a pig-to-baboon orthotopic cardiac xenograft model. Journal of Thoracic and Cardiovascular Surgery, 1998, 115, 1342-1349.	0.4	59
205	Mechanisms of recovery from experimental autoimmune encephalomyelitis: T cell deletion and immune deviation in myelin basic protein T cell receptor transgenic mice. Journal of Neuroimmunology, 1998, 82, 149-159.	1.1	39
206	Endothelial activation and cytokine expression in human acute cardiac allograft rejection. Pathology, 1998, 30, 24-29.	0.3	55
207	INTRAVENOUS INFUSION OF Gal??1-3Gal OLIGOSACCHARIDES IN BABOONS DELAYS HYPERACUTE REJECTION OF PORCINE HEART XENOGRAFTS. Transplantation, 1998, 65, 346-353.	0.5	127
208	BLOCKADE OF VERY LATE ANTIGEN-4 INTEGRIN BINDING TO FIBRONECTIN IN ALLOGRAFT RECIPIENTS. Transplantation, 1998, 65, 854-859.	0.5	28
209	INDEFINITE SURVIVAL OF SKIN ALLOGRAFTS IN ADULT THYMECTOMIZED, ANTILYMPHOCYTE SERUM-TREATED MICE GIVEN BONE MARROW AND THYMUS GRAFTS OF DONOR ORIGIN1. Transplantation, 1998, 65, 1036-1043.	0.5	10
210	TRANSIENT COMPLEMENT INHIBITION PLUS T-CELL IMMUNOSUPPRESSION INDUCES LONG-TERM SURVIVAL OF MOUSE-TO-RAT CARDIAC XENOGRAFTS1, 2. Transplantation, 1998, 65, 1210-1215.	0.5	36
211	EFFECTS OF EXPLOSIVE BRAIN DEATH ON CYTOKINE ACTIVATION OF PERIPHERAL ORGANS IN THE RAT1. Transplantation, 1998, 65, 1533-1542.	0.5	373
212	SURVIVAL OF ACCOMMODATED CARDIAC XENOGRAFTS UPON RETRANSPLANTATION INTO CYCLOSPORINE-TREATED RECIPIENTS1,2. Transplantation, 1998, 65, 1563-1569.	0.5	31
213	IMPORTANCE OF T CELLS TO ACCELERATED REJECTION AND ACCEPTANCE OF RENAL ALLOGRAFTS IN SENSITIZED RAT RECIPIENTS1. Transplantation, 1998, 66, 1354-1361.	0.5	4
214	Loss of ATP Diphosphohydrolase Activity with Endothelial Cell Activation. Journal of Experimental Medicine, 1997, 185, 153-164.	4.2	278
215	Impact of alloimmunity on chronic tissue remodelling: role of cytokines and protective genes in the vessel wall. Transplant Immunology, 1997, 5, 277-281.	0.6	3
216	Xenograft accommodation is accompanied by intragraft Th2 cytokines and vascular expression of protective genes. Xenotransplantation, 1997, 4, 154-160.	1.6	6

#	Article	IF	Citations
217	Modification of vascular responses in xenotransplantation: Inflammation and apoptosis. Nature Medicine, 1997, 3, 944-948.	15.2	108
218	The past, present, and future of renal xenotransplantation. Kidney International, 1997, 51, 932-944.	2.6	23
219	Delayed Xenograft Rejection. World Journal of Surgery, 1997, 21, 917-923.	0.8	42
220	EFFECT OF PORCINE ENDOTHELIAL TISSUE FACTOR PATHWAY INHIBITOR ON HUMAN COAGULATION FACTORS1. Transplantation, 1997, 63, 749-758.	0.5	113
221	SYNTHETIC MHC CLASS I PEPTIDE PROLONGS CARDIAC SURVIVAL AND ATTENUATES TRANSPLANT ARTERIOSCLEROSIS IN THE LEWIS???FISCHER 344 MODEL OF CHRONIC ALLOGRAFT REJECTION. Transplantation, 1997, 64, 14-19.	0.5	26
222	EFFECTS OF LEFLUNOMIDE AND DEOXYSPERGUALIN IN THE GUINEA PIG???RAT CARDIAC MODEL OF DELAYED XENOGRAFT REJECTION. Transplantation, 1997, 64, 696-704.	0.5	31
223	ANTI-CD4 MONOCLONAL ANTIBODY-INDUCED ALLOGRAFT TOLERANCE IN RATS DESPITE PERSISTENCE OF DONOR-REACTIVE T CELLS1. Transplantation, 1997, 64, 1181-1187.	0.5	66
224	DONOR ANTIGEN IS NECESSARY FOR THE PREVENTION OF CHRONIC REJECTION IN CTLA4IG-TREATED MURINE CARDIAC ALLOGRAFT RECIPIENTS1,2. Transplantation, 1997, 64, 1646-1650.	0.5	103
225	Mechanisms of Oral Tolerance by MHC Peptides. Annals of the New York Academy of Sciences, 1996, 778, 338-345.	1.8	24
226	Oral Tolerance to Insulin and the Insulin B-Chain.. Annals of the New York Academy of Sciences, 1996, 778, 346-357.	1.8	14
227	Protective genes expressed in endothelial cells of second hamster heart transplants to rats carrying an accommodated first graft. Xenotransplantation, 1996, 3, 279-286.	1.6	15
228	INDUCTION OF LONG-TERM RAT RENAL ALLOGRAFT SURVIVAL BY PRETRANSPLANT T CELL RECEPTOR-??/??-TARGETED THERAPY1. Transplantation, 1996, 61, 336-339.	0.5	8
229	THE EFFECTS OF NONDEPLETING CD4 TARGETED THERAPY IN PRESENSITIZED RAT RECIPIENTS OF CARDIAC ALLOGRAFTS1,2. Transplantation, 1996, 61, 804-811.	0.5	50
230	THROMBIN INHIBITION IN AN EX VIVO MODEL OF PORCINE HEART XENOGRAFT HYPERACUTE REJECTION1. Transplantation, 1996, 61, 862-868.	0.5	54
231	??/??-T CELL RECEPTOR-DIRECTED THERAPY IN RAT ALLOGRAFT RECIPIENTS. Transplantation, 1996, 61, 948-956.	0.5	27
232	INHIBITION OF PLATELET INTEGRIN GPIIbIIIa PROLONGS SURVIVAL OF DISCORDANT CARDIAC XENOGRAFTS1,2. Transplantation, 1996, 62, 1-5.	0.5	60
233	EFFECT OF REPETITIVE HIGH-DOSE TREATMENT WITH SOLUBLE COMPLEMENT RECEPTOR TYPE 1 AND COBRA VENOM FACTOR ON DISCORDANT XENOGRAFT SURVIVAL1,2. Transplantation, 1996, 62, 336-342.	0.5	49
234	KEY ROLE OF THE ALTERNATE COMPLEMENT PATHWAY IN HYPERACUTE REJECTION OF RAT HEARTS TRANSPLANTED INTO FETAL SHEEP1. Transplantation, 1996, 62, 407-411.	0.5	14

#	Article	IF	Citations
235	APYRASE ADMINISTRATION PROLONGS DISCORDANT XENOGRAFT SURVIVAL1,2,3,4. Transplantation, 1996, 62, 1739-1743.	0.5	75
236	IMMUNOMODULATORY EFFECTS OF THE ALKALOID SINOMENINE IN THE HIGH RESPONDER ACI-TO-LEWIS CARDIAC ALLOGRAFT MODEL1. Transplantation, 1996, 62, 1855-1860.	0.5	39
237	T CELL INDEPENDENCE OF MACROPHAGE AND NATURAL KILLER CELL INFILTRATION, CYTOKINE PRODUCTION, AND ENDOTHELIAL ACTIVATION DURING DELAYED XENOGRAFT REJECTION1,2,3. Transplantation, 1996, 62, 1920-1927.	0.5	128
238	CD28-B7 T CELL COSTIMULATORY BLOCKADE BY CTLA4Ig IN THE RAT RENAL ALLOGRAFT MODEL1,2. Transplantation, 1996, 62, 1942-1945.	0.5	66
239	Î±/Î²-T CELL RECEPTOR-DIRECTED THERAPY IN RAT CARDIAC ALLOGRAFT RECIPIENTS. Transplantation, 1995, 59, 78-84.	0.5	20
240	DOWNREGULATION OF INTRAGRAFT IFN-Î³ EXPRESSION CORRELATES WITH INCREASED IgG1 ALLOANTIBODY RESPONSE FOLLOWING INTRATHYMIC IMMUNOMODULATION OF SENSITIZED RAT RECIPIENTS1,2. Transplantation, 1995, 60, 1516-1524.	0.5	37
241	BINDING OF ACTIVATED PROTEIN C TO A SPECIFIC RECEPTOR ON HUMAN MONONUCLEAR PHAGOCYTES INHIBITS INTRACELLULAR CALCIUM SIGNALING AND MONOCYTE-DEPENDENT PROLIFERATIVE RESPONSES1,2. Transplantation, 1995, 60, 1525-1532.	0.5	109
242	Early Rejection of Human Cardiac Allografts Is a Risk Factor for Multiple Rejection Episodes. International Journal of Surgical Pathology, 1995, 3, 9-15.	0.4	0
243	Role of Endothelial Cells in Transplantation (Part 1 of 2). International Archives of Allergy and Immunology, 1995, 106, 305-314.	0.9	88
244	THE ALLOANTIBODY NETWORK FOLLOWING INTRATHYMIC IMMUNOMODULATION OF SENSITIZED RAT RECIPIENTS OF CARDIAC ALLOGRAFTS1,2. Transplantation, 1995, 59, 590-597.	0.5	0
245	UPREGULATION OF CYTOKINES ASSOCIATED WITH MACROPHAGE ACTIVATION IN THE LEWIS-TO-F344 RAT TRANSPLANTATION MODEL OF CHRONIC CARDIAC REJECTION1,2. Transplantation, 1995, 59, 572-578.	0.5	3
246	Endothelial Cell Activation and Thromboregulation during Xenograft Rejection. Immunological Reviews, 1994, 141, 5-30.	2.8	205
247	Long-Term Kidney Isografts Develop Functional and Morphologic Changes That Mimic Those of Chronic Allograft Rejection. Annals of Surgery, 1994, 220, 425-435.	2.1	143
248	ABROGATION BY RAPAMYCIN OF ACCELERATED REJECTION IN SENSITIZED RATS BY INHIBITION OF ALLOANTIBODY RESPONSES AND SELECTIVE SUPPRESSION OF INTRAGRAFT MONONUCLEAR AND ENDOTHELIAL CELL ACTIVATION, CYTOKINE PRODUCTION, AND CELL ADHESION1,2. Transplantation, 1994, 57, 933-941.	0.5	44
249	INTRATHYMIC INJECTION OF DONOR-SPECIFIC X-IRRADIATION-SENSITIVE SPLEEN CELLS ABROGATES ACCELERATED REJECTION OF CARDIAC ALLOGRAFTS IN SENSITIZED RATS1. Transplantation, 1994, 58, 80-86.	0.5	0
250	Chronic Rejection in Experimental Cardiac Transplantation: Studies in the Lewis-F344 Model. Immunological Reviews, 1993, 134, 5-19.	2.8	96
251	Iron Chelation Suppresses Mononuclear Cell Activation, Modifies Lymphocyte Migration Patters, And Prolongs Rat Cardiac Allograft Survival In Rats. Transplantation, 1993, 56, 1182-1187.	0.5	12
252	THYMIC RECOGNITION OF CLASS II MAJOR HISTOCOMPATIBILITY COMPLEX ALLOPEPTIDES INDUCES DONOR-SPECIFIC UNRESPONSIVENESS TO RENAL ALLOGRAFTS. Transplantation, 1993, 56, 461-465.	0.5	133

#	Article	IF	Citations
253	MECHANISM OF A CLINICALLY RELEVANT PROTOCOL TO INDUCE TOLERANCE OF CARDIAC ALLOGRAFTS. Transplantation, 1993, 56, 1309-1314.	0.5	12
254	ORAL, BUT NOT INTRAVENOUS, ALLOANTIGEN PREVENTS ACCELERATED ALLOGRAFT REJECTION BY SELECTIVE INTRAGRAFT TH2 CELL ACTIVATION. Transplantation, 1993, 55, 1112-1117.	0.5	114
255	BLOCKING OF MONONUCLEAR CELL ACCUMULATION, CYTOKINE PRODUCTION, AND ENDOTHELIAL ACTIVATION WITHIN RAT CARDIAC ALLOGRAFTS BY CD4 MONOCLONAL ANTIBODY THERAPY. Transplantation, 1992, 53, 1276-1280.	0.5	33
256	DOWN-REGULATION OF THE IMMUNE RESPONSE TO HISTOCOMPATIBILITY ANTIGENS AND PREVENTION OF SENSITIZATION BY SKIN ALLOGRAFTS BY ORALLY ADMINISTERED ALLOANTIGEN1. Transplantation, 1992, 53, 163-166.	0.5	84
257	CD4 MONOCLONAL ANTIBODIES IN ORGAN TRANSPLANTATIONâ€"A REVIEW OF PROGRESS1. Transplantation, 1991, 52, 579-589.	0.5	58
258	DIFFERENTIAL ROLE OF CD4+ CELLS IN THE SENSITIZATION AND EFFECTOR PHASES OF ACCELERATED GRAFT REJECTION. Transplantation, 1991, 51, 226-231.	0.5	20
259	MODULATION OF ACCELERATED REJECTION OF CARDIAC ALLOGRAFTS IN SENSITIZED RATS BY ANTI-INTERLEUKIN 2 RECEPTOR MONOCLONAL ANTIBODY AND CYCLOSPORINE THERAPY. Transplantation, 1991, 51, 300-304.	0.5	15
260	Activated (IL-2R+) intraglomerular mononuclear cells in crescentic glomerulonephritis. Kidney International, 1991, 39, 793-798.	2.6	61
261	THE MECHANISM OF SYNERGISTIC INTERACTION BETWEEN ANTI-INTERLEUKIN 2 RECEPTOR MONOCLONAL ANTIBODY AND CYCLOSPORINE THERAPY IN RAT RECIPIENTS OF ORGAN ALLOGRAFTS. Transplantation, 1990, 50, 545-550.	0.5	24
262	CYCLOSPORINE AND ANTI-INTERLEUKIN 2 RECEPTOR MONOCLONAL ANTIBODY THERAPY SUPPRESS ACCELERATED REJECTION OF RAT CARDIAC ALLOGRAFTS THROUGH DIFFERENT EFFECTOR MECHANISMS. Transplantation, 1990, 49, 416-421.	0.5	42
263	DIFFERENTIAL EFFECTS OF INTERLEUKIN 2 RECEPTOR-TARGETED THERAPY ON HEART AND KIDNEY ALLOGRAFTS IN RATS. Transplantation, 1990, 49, 1124-1129.	0.5	8
264	Mononuclear cell activation and decreased renal function in IgA nephropathy with crescents. Kidney International, 1990, 37, 1552-1556.	2.6	72
265	Antimetastatic Agents. II. Summary of the Interactions of Tumor Cells with Blood Coagulation Factors, Platelets, Fibrinolytic Factors, and Inflammatory Cells and Their Soluble Mediators: Potential for Therapeutic Interventions. Seminars in Thrombosis and Hemostasis, 1988, 14, 126-132.	1.5	8
266	Antimetastatic Agents. I. Role of Cellular Procoagulants in the Pathogenesis of Fibrin Deposition in Cancer and the Use of Anticoagulants and/or Antiplatelet Drugs in Cancer Treatment. Seminars in Thrombosis and Hemostasis, 1988, 14, 88-94.	1.5	54
267	[78] Immunohistological studies with monoclonal antibodies. Methods in Enzymology, 1986, 121, 828-848.	0.4	13
268	INHIBITION OF RAT SKIN ALLOGRAFT REJECTION BY CYCLOSPORINE IN SITU CHARACTERIZATION OF THE IMPAIRED LOCAL IMMUNE RESPONSE. Transplantation, 1986, 41, 734-738.	0.5	6
269	IMMUNOHISTOLOGICAL ANALYSIS OF SERIAL BIOPSIES TAKEN DURING HUMAN RENAL ALLOGRAFT REJECTION. Transplantation, 1985, 39, 430-438.	0.5	65
270	Cellular Composition of Crescents in Human Rapidly Progressive Glomerulonephritis Identified Using Monoclonal Antibodies. American Journal of Nephrology, 1984, 4, 177-181.	1.4	53

#	Article	IF	Citations
271	Production of monoclonal antibodies to fibronectin, type iv collagen and other antigens of the human glomerulus. Pathology, 1984, 16, 197-206.	0.3	33
272	COMPOSITION OF INTERSTITIAL CELLULAR INFILTRATE IDENTIFIED BY MONOCLONAL ANTIBODIES IN RENAL BIOPSIES OF REJECTING HUMAN RENAL ALLOGRAFTS. Transplantation, 1983, 35, 458-462.	0.5	147
273	A Comparison of Fixatives and Immunohistochemical Technics for Use with Monoclonal Antibodies to Cell Surface Antigens. American Journal of Clinical Pathology, 1982, 78, 825-831.	0.4	131
274	Cellular immune mechanisms in human glomerulonephritis: The role of mononuclear leucocytes. Seminars in Immunopathology, 1982, 5, 269-296.	4.0	50
275	The immunohistochemical demonstration of major histocompatibility antigens in the human kidney using monoclonal antibodies. Pathology, 1982, 14, 409-414.	0.3	57
276	Tissue culture of isolated glomeruli from patients with glomerulonephritis. Kidney International, 1980, 17, 515-527.	2.6	48
277	Nuclear Coregulatory Complexes in Tregs as Targets to Promote Anticancer Immune Responses. Frontiers in Immunology, 0, 13, .	2.2	3